Decreases were also seen for itching and foreign body sensation, though not statistically significant. Relative to the vehicle control, significant decreases from baseline to day 42 were seen in the FD hPL 30% group with regard to ocular discomfort (mean decrease = -18.04 P = 0.018), frequency of burning/stinging (-20.23 P = 0.022), eye discomfort (-32.97 P < 0.001), eye dryness (-21.61 P = 0.020), pain (-15.12 P = 0.044), photophobia (-24.33 P = 0.0125), and grittiness (-20.08 P = 0.0185). The ocular symptom frequency was assessed on a 100-point VAS.įD hPL 10% and 30% were safe and well tolerated. Secondary outcomes were changes from baseline to day 42 in ocular discomfort, OSDI, fluorescein corneal staining, and lissamine green conjunctival staining relative to the vehicle control. Primary outcome safety measures were ocular and systemic adverse events and the number of patients in each group with clinically significant change from normal to abnormal in any ocular findings. After 42 days, control patients were offered 42 days of open-label treatment with 30% FD hPL. Sixty-four adult patients were stratified by 'symptom severity' (Ocular Surface Disease Index, ocular discomfort Visual Analog Scale (VAS), ocular symptom frequency, and use of artificial tears) and then randomized 1:1:1 to CAM-101 (FD hPL) at 10% or 30% concentration or an electrolyte (Plasma-Lyte A) vehicle control, 1 drop in both eyes, 4 times daily, for 42 days.

The purpose of the study was to evaluate, as a pilot trial, safety and tolerability of CAM-101 10% and 30% topical ophthalmic fibrinogen-depleted human platelet lysate (FD hPL) solution in patients with dry eye disease (DED) secondary to graft-versus-host disease (GvHD) after 6 weeks of treatment.Ī phase I/II, pilot, prospective, multicenter, randomized, double-masked clinical trial.

12 Winship Cancer Institute of Emory University, Atlanta, Georgia.

11 Woolfson Eye Institute, Atlanta, Georgia.

10 Cambium Medical Technologies LLC, Atlanta, Georgia.

9 UPMC Eye Center, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.

8 Department of Ophthalmology and Visual Neurosciences, University of Minnesota, Minneapolis, Minnesota.

7 Duke University Eye Center, Durham, North Carolina.

6 Doheny Eye Center, UCLA, Los Angeles, California.

5 Department of Ophthalmology, School of Medicine, Stanford University, Stanford, California.

4 Eye Associates Northwest PC, Seattle, Washington.3 Department of Ophthalmology, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, Massachusetts.2 Casey Eye Institute, and Department of Ophthalmology, Oregon Health and Science University, Portland, Oregon.1 WK Kellogg Eye Center, University of Michigan, Ann Arbor, Michigan.In 2022, Pérez reached the summit of Makalu without supplemental oxygen. In 2021, Pérez climbed on Dhaulagiri but was not able to reach the summit. Alison Hargreaves being the first, in 1995 who climbed unsupported and without supplemental oxygen but tragically died in a storm during descent. In so doing, she became the second woman to reach the summit of Mount Everest and K2 in the same year. In 2019, Pérez became the first woman from the Americas to reach the summit of K2 without supplemental oxygen. In 2019, she successfully guided clients to the summit via the northeast ridge. In 2016, she became the first woman from Latin America to reach the summit without supplemental oxygen. Pérez has spent time on Mount Everest as both a mountain guide and a climber.

In 2015, Pérez reached the summit of Broad Peak without supplemental oxygen. In 2014, Pérez completed a solo ascent of Cho Oyu without supplemental oxygen. In 2012, Pérez reached the summit of Manaslu without supplemental oxygen. When Pérez was four years old her father took her to a 14,000-foot volcano near their home at Quito, Ecuador, which inspired her to become a mountain climber. In 2019 she became the first woman to successfully summit both Everest and K2 in the same year (in 1995 Alison Hargreaves reached both summits unsupported and without supplemental oxygen but died descending K2), and the first woman from the Americas to summit K2 without supplemental oxygen. Carla Pérez (born 28 December 1982) is an Ecuadorian mountaineer, and mountain guide.

Carla perez vas